TP53 and neoplasm: The p53 mutation at three acetylation sites (K117R+K161R+K162R, 3KR mutant) loses its ability to induce cell cycle arrest, senescence, and apoptosis, yet still is capable of regulating ROS production and suppressing tumor formation [53].